Oral Cavity Cancer
Mouth cancer · Oral squamous cell carcinoma (OSCC) · Tongue cancer · Buccal mucosa cancer | ICD-O-3 C02–C06 (GLOBOCAN groups C00–C06 as lip + oral cavity)
Oral cavity cancer is a squamous cell carcinoma arising on the tongue, floor of mouth, buccal (cheek) mucosa, gums, hard palate or retromolar region. It is the largest head and neck cancer subsite worldwide and is overwhelmingly concentrated in South Asia, where chewing tobacco, betel quid and areca nut are common. Surgery with clear margins and reconstruction is the main curative treatment.
The oral cavity is the part of the mouth a dentist can see and touch. Unlike oropharyngeal cancer, most oral cavity cancers are caused by direct contact carcinogens — smoked and smokeless tobacco, areca nut, betel quid and heavy alcohol — rather than HPV. In India and neighbouring countries the tumour often starts on the buccal mucosa, exactly where the quid is held against the cheek.
Because the mouth is visible, oral cancer should be detectable early. In practice many patients in high-burden countries present with locally advanced disease. A non-healing ulcer, a white or red patch, a lump or a loose tooth lasting more than two to three weeks should be biopsied, not treated repeatedly as an infection.
Where in the world is oral cavity cancer common?
about 317,500 new oral cavity cancer cases (C02–C06) were estimated worldwide in 2022 (male ASR 4.6 and female ASR 2.0 per 100,000; 41.9% of all lip/oral/pharyngeal cancers in 2022).
Using the wider GLOBOCAN grouping that includes lip (C00–C06), the 2022 total was 389,846 cases with an ASR of 4.0 per 100,000.
| Region / country | What the data show |
|---|---|
| India | 143,759 new oral cancer cases and 79,979 deaths in 2022 — 10.2% of all Indian cancers, ASR 10.1/100,000. Men account for ~75% (male ASR 15.6). Tobacco and areca nut explain roughly 70–80% of cases. |
| South-Central Asia (Bangladesh, Pakistan, Sri Lanka) | Oral cavity cancer makes up 59.8% of all lip/oral/pharyngeal cancers in the region. Male ASRs: Sri Lanka 12.4, Bangladesh 12.0, Pakistan 11.3; female ASRs: Bangladesh 6.4, Pakistan 5.9. |
| Papua New Guinea & Melanesia | The highest female oral cavity ASR worldwide (8.1/100,000) and male ASR 9.6, linked to areca nut and betel quid chewing. |
| Southern Africa & parts of Western Africa | Oral cavity represents 48.8% of the lip/oral/pharyngeal burden in Southern Africa, with elevated male rates. |
| Southern & Eastern Europe | Oral cavity accounts for 38.8% of Southern European and 14.1% of Eastern European lip/oral/pharyngeal cancers, largely tobacco- and alcohol-related. |
| United States | About 58,000 Americans are diagnosed with oral cancer each year with around 12,000 deaths; substantially lower ASR than South Asia. |
What are the risk factors?
- Chewing betel quid / areca nut (with or without tobacco) — IARC Group 1 carcinogen
- Smokeless tobacco products: gutka, khaini, zarda, snuff, toombak, iqmik
- Cigarette, bidi or cigar smoking
- Heavy alcohol use, with a multiplicative effect when combined with tobacco
- Chronic mechanical irritation from a sharp tooth or ill-fitting denture
- Oral potentially malignant disorders: leukoplakia, erythroplakia, oral submucous fibrosis
- Prior head and neck cancer and, rarely, immunosuppression
What are the signs and symptoms?
- A mouth ulcer or sore that does not heal within 2–3 weeks
- A white patch (leukoplakia) or red patch (erythroplakia) on the tongue, cheek or gum
- A lump, thickening or numbness in the tongue, cheek or floor of mouth
- Restricted mouth opening or burning sensation from oral submucous fibrosis
- Loose teeth, bleeding gums or a non-healing extraction socket
- Pain or difficulty swallowing, altered speech, or a hard neck lump
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Incisional biopsy of the suspicious lesion — the only way to confirm invasive cancer
- Bimanual palpation and measurement of the lesion, with photography for the record
- Contrast CT or MRI of the oral cavity and neck to assess bone invasion, tongue muscle involvement and nodes
- Ultrasound-guided FNA of any suspicious cervical node; chest CT / PET-CT for advanced disease
- Dental panoramic radiograph, dental clearance and nutritional assessment before surgery or radiotherapy
- Pathology review for depth of invasion, margins, perineural invasion, lymphovascular invasion and extranodal extension
AJCC 8th edition TNM for oral cavity cancer incorporates depth of invasion (DOI) into the T category, because thicker tumours have a higher risk of occult neck metastasis. This is why even a clinically node-negative tongue cancer with DOI above 3–4 mm often receives an elective neck dissection or sentinel lymph node biopsy.
What are the treatment options?
- Wide surgical excision with a macroscopic margin of at least 1 cm where anatomy permits, aiming for clear microscopic margins
- Elective or therapeutic neck dissection (or sentinel node biopsy in selected early tongue cancers)
- Immediate reconstruction — local flap, pedicled flap or microvascular free flap (radial forearm, anterolateral thigh, fibula for bone)
- Postoperative radiotherapy for close/positive margins, pT3–T4, multiple nodes or perineural invasion; concurrent chemoradiotherapy for positive margins or extranodal extension
- Primary radiotherapy or chemoradiotherapy for patients unfit for, or declining, major surgery
- Immunotherapy (PD-1 inhibitors) and/or chemotherapy for recurrent or metastatic disease; clinical trials where available
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
Prognosis depends most on stage, margin status, depth of invasion and nodal involvement. Early, completely resected oral cavity cancers are commonly reported with five-year survival in the 70–90% range, whereas locally advanced disease with positive margins or extranodal extension is substantially worse. Population registry data from South Asia show lower survival than high-income countries, largely because of later stage at diagnosis.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- Stop all forms of tobacco and areca nut / betel quid — the single most effective intervention
- Limit alcohol, especially in combination with tobacco
- Dental review to smooth sharp teeth and repair ill-fitting dentures
- Regular oral examination by a dentist or trained clinician for high-risk users (visual inspection is low-cost and evidence-based)
- Early biopsy or referral for any white/red patch or non-healing ulcer; treat oral submucous fibrosis early
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
Chinese head and neck units perform a high volume of oral cancer resections with immediate microvascular free-flap reconstruction. For international patients the main practical benefits are short waiting times, combined ablative-and-reconstructive surgery in one admission, and a written English operative and follow-up plan.
- Bring the original biopsy slides or block, contrast MRI/CT images on DICOM, a dental panoramic radiograph and any prior treatment records.
- Ask whether reconstruction will use a free flap, what donor site is planned, and how speech, swallowing and tongue mobility will be rehabilitated.
- Confirm in writing whether postoperative radiotherapy is anticipated, because that changes how long you must remain in China.
- Ask about the pathology reporting standard (depth of invasion, margins, extranodal extension) so your local oncologist can continue follow-up.
Cost guidance: As an illustrative planning range, wide excision with neck dissection and free-flap reconstruction is often budgeted at ¥100,000–¥220,000 (about US$14,000–30,000), with adjuvant radiotherapy or chemoradiotherapy adding ¥40,000–¥120,000. These are budgeting figures, not a quotation; an itemised estimate requires review of your imaging and pathology.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 15 questions about oral cavity cancer
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
3 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
4 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Prognosis & follow-up
1 questionSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
3 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
2 questionsWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is oral cavity cancer?
Oral cavity cancer is a squamous cell carcinoma arising on the tongue, floor of mouth, buccal (cheek) mucosa, gums, hard palate or retromolar region. It is the largest head and neck cancer subsite worldwide and is overwhelmingly concentrated in South Asia, where chewing tobacco, betel quid and areca nut are common. Surgery with clear margins and reconstruction is the main curative treatment.
Where in the world is oral cavity cancer most common?
Oral Cavity Cancer is not evenly distributed: the highest-burden regions are India, South-Central Asia (Bangladesh, Pakistan, Sri Lanka) and Papua New Guinea & Melanesia. In 2022 there were about 317,500 new oral cavity cancer cases (C02–C06) worldwide (male ASR 4.6 and female ASR 2.0 per 100,000; 41.9% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for oral cavity cancer?
The main recognised risk factors for oral cavity cancer are chewing betel quid / areca nut (with or without tobacco) — IARC Group 1 carcinogen, smokeless tobacco products: gutka, khaini, zarda, snuff, toombak, iqmik and cigarette, bidi or cigar smoking. Risks differ by region: India has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of oral cavity cancer?
The common early signs are a mouth ulcer or sore that does not heal within 2–3 weeks, a white patch (leukoplakia) or red patch (erythroplakia) on the tongue, cheek or gum, a lump, thickening or numbness in the tongue, cheek or floor of mouth and restricted mouth opening or burning sensation from oral submucous fibrosis. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is oral cavity cancer diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for oral cavity cancer?
Treatment is stage- and site-specific, and usually combines wide surgical excision with a macroscopic margin of at least 1 cm where anatomy permits, aiming for clear microscopic margins, elective or therapeutic neck dissection (or sentinel node biopsy in selected early tongue cancers) and immediate reconstruction — local flap, pedicled flap or microvascular free flap (radial forearm, anterolateral thigh, fibula for bone). Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for oral cavity cancer?
Prognosis depends most on stage, margin status, depth of invasion and nodal involvement. Early, completely resected oral cavity cancers are commonly reported with five-year survival in the 70–90% range, whereas locally advanced disease with positive margins or extranodal extension is substantially worse. Population registry data from South Asia show lower survival than high-income countries, largely because of later stage at diagnosis.
Can oral cavity cancer be prevented?
Many cases are preventable. The most useful steps for oral cavity cancer are stop all forms of tobacco and areca nut / betel quid — the single most effective intervention, limit alcohol, especially in combination with tobacco and dental review to smooth sharp teeth and repair ill-fitting dentures. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
Why is oral cancer so common in India and South Asia?
Because chewing tobacco, betel quid and areca nut are widely used and are held directly against the cheek and gum for long periods. These products are IARC Group 1 carcinogens; an estimated 70–80% of Indian oral cancers are attributable to tobacco and areca nut, producing a characteristic buccal mucosa cancer pattern.
When should a mouth ulcer be biopsied?
Any oral ulcer, white or red patch, lump or unexplained loose tooth that persists for more than two to three weeks should be examined by a dentist or ENT surgeon and usually biopsied. Pain is not a reliable guide — early oral cancers are often painless, and repeated courses of antibiotics or antifungal treatment are the commonest cause of diagnostic delay.
What is depth of invasion and why does it change the operation?
Depth of invasion (DOI) measures how far the tumour has grown downward from the surface, in millimetres. In AJCC 8th edition it upstages the T category, because thicker tongue and floor-of-mouth cancers have a much higher rate of microscopic neck-node spread even when the neck feels normal on examination.
Will I need reconstructive (free-flap) surgery after oral cancer removal?
Larger defects of the tongue, floor of mouth or jaw usually require immediate reconstruction with a microvascular free flap — tissue transferred from the forearm, thigh or fibula with its blood vessels reconnected under a microscope. The goal is to restore speech, swallowing, tongue mobility and facial contour in the same admission as tumour removal.
What is oral submucous fibrosis and does it turn into cancer?
Oral submucous fibrosis is a chronic, scarring condition caused mainly by areca nut chewing that progressively limits mouth opening and causes burning and stiffness. It is an oral potentially malignant disorder: a minority of cases undergo malignant transformation to squamous cell carcinoma, and the risk rises with continued areca nut use.
Why do some international patients choose oral cancer surgery in China?
The usual reasons are short waiting times, high procedural volumes for oral cancer ablation and microvascular reconstruction, and lower total cost than private care in the US or Western Europe. Treatment can often begin within days of an in-person evaluation, which matters because delays in head and neck cancer surgery worsen outcomes.
What does oral cancer surgery in China cost for an international patient?
As a planning range, wide excision with neck dissection and free-flap reconstruction is commonly budgeted at ¥100,000–¥220,000 (roughly US$14,000–30,000), with adjuvant radiotherapy or chemoradiotherapy adding ¥40,000–¥120,000. Costs vary widely with stage, flap type, ICU stay and complications. These figures are not a quotation.
Sources for this topic
- Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022
- Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison
- Smokeless Tobacco and Oral Cancer in Global Perspective
- Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy
- Global Cancer Observatory (GLOBOCAN 2022)
- NCCN Guidelines for Patients: Head and Neck Cancers
- Cancer Stat Facts: Oral Cavity and Pharynx Cancer
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV)
Ask about oral cavity cancer treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.